CAR-T immunotherapy for hematologic cancers: restrictions and potential strategies

Jiayan Li

doi:10.1117/12.3013063

8 January 2024 CAR-T immunotherapy for hematologic cancers: restrictions and potential strategies

Jiayan Li

Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129243C (2024) https://doi.org/10.1117/12.3013063
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom

Abstract

Hematologic cancers, or malignancies of the blood system, include mainly leukemia, multiple myeloma, and lymphoma. The mainstream treatment for hematologic malignancies is intravenous chemotherapy, in which chemotherapy drugs are infused intravenously to reach various parts of the body with blood circulation and kill tumor cells present in the blood or tissues. Alternatively, local chemotherapy is used, which is mainly administered through a puncture needle into the spinal canal to kill lymphoma cells. Although the cancer may go into full or partial remission, the chance of recurrence or refractory cancers remains significant and is associated by extremely severe toxicity. So more efficient and safer treatment strategies need to be proposed. T cells genetically engineered with chimeric antigen receptors (CAR-T) for the treatment of hematologic cancers have been heavily investigated over the past decade and represent a new era of therapeutic strategies. In this paper,There is a discussion of the various obstacles and potential options for chimeric antigen receptor CAR-T treatment for hematologic malignancies.

(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.

Citation Download Citation

Jiayan Li "CAR-T immunotherapy for hematologic cancers: restrictions and potential strategies", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129243C (8 January 2024); https://doi.org/10.1117/12.3013063

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available